Figure 2.
Kaplan-Meier plots of overall survival by treatment arm and blood TMB high/low status. OS by treatment arm in (A) bTMB ≥20 mut/Mb subgroup and (B) bTMB <20 mut/Mb subgroup. Data cut-off: 12 March 2021. HRs and CIs were estimated from an unstratified Cox proportional hazards model. bTMB, blood tumor mutational burden; CI, confidence interval; CT, chemotherapy; D, durvalumab; HR, hazard ratio; Mb, megabase; mut, mutations; OS, overall survival; T, tremelimumab.
